Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in mice treated neonatally with zidovudine and didanosine

Mutagenesis

Volumn 19, Issue 4, 2004, Pages 307-311

  Von Tungeln, Linda S ^a   Dobrovolsky, Vasily N ^a   Bishop, Michelle E ^a   Shaddock, Joseph G ^a   Heflich, Robert H ^a   Beland, Frederick A ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BROXURIDINE; DIDANOSINE; DIMETHYL SULFOXIDE; ETHYLNITROSOUREA; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MUTANT PROTEIN; NUCLEOSIDE ANALOG; THYMIDINE KINASE; ZIDOVUDINE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; BREEDING; CONTROLLED STUDY; DRUG POTENTIATION; ERYTHROCYTE; FEMALE; GENE FREQUENCY; GENE LOSS; GENE MUTATION; GENOTOXICITY; IN VIVO STUDY; MALE; MICRONUCLEUS; MOUSE; MOUSE STRAIN; MUTAGENICITY; MUTATIONAL ANALYSIS; NEWBORN; NONHUMAN; PERINATAL DRUG EXPOSURE; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANIMALS, NEWBORN; ANTI-HIV AGENTS; BONE MARROW CELLS; DIDANOSINE; DRUG INTERACTIONS; FEMALE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LOSS OF HETEROZYGOSITY; LYMPHOCYTES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRONUCLEUS TESTS; MUTAGENS; THYMIDINE KINASE; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 3543129486     PISSN: 02678357     EISSN: None     Source Type: Journal    
DOI: 10.1093/mutage/geh033     Document Type: Article

References (36)

1. Avramis,V.I., Markson,W., Jackson,R.L. and Gomperts,E. (1989) Biochemical pharmacology of zidovudine in human T-lymphoblastoid cells (CEM). AIDS, 3, 417-422.
2. Carr,A. and Cooper,D.A. (2000) Adverse effects of antiretroviral therapy. Lancet, 356, 1423-1430.
3. Cheng,Y.-c., Dutschman,G.E., Bastow,K.F., Sarngadharan,M.G. and Ting,R.Y.C. (1987) Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J. Biol. Chem., 262, 2187-2189.
4. Diwan,B.A., Riggs,C.W., Logsdon,D., Haines,D.C., Olivero,O.A., Rice,J.M., Yuspa,S.H., Poirier,M.C. and Anderson,L.M. (1999) Multiorgan transplacental and neonatal carcinogenicity of 3′-azido-3′-deoxythymidine in mice. Toxicol. Appl. Pharmacol., 161, 82-99.
5. +/- mouse model for detecting in vivo mutation in an endogenous, autosomal gene. Mutat. Res., 423, 125-136.
6. Dobrovolsky,V.N., Chen,T. and Heflich,R.H. (1999b) Molecular analysis of in vivo mutations induced by N-ethyl-N-nitrosourea in the autosomal Tk and the X-linked Hprt genes of mouse lymphocytes. Environ. Mol. Mutagen., 34, 30-38.
7. Dornsife,R.E., St Clair,M.H., Huang,A.T., Panella,T.J., Koszalka,G.W., Burns,C.L. and Averett,D.R. (1991) Anti-human immunodeficiency virus synergism by zidovudine (3′-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob. Agents Chemother., 35, 322-328.
8. Faulds,D. and Brogden,R.N. (1992) Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs, 44, 94-116.
9. Furman,P.A., Fyfe,J.A., St. Clair,M.H., Weinhold,K., Rideout,J.L., Freeman,G.A., Nusinoff Lehrman,S., Bolognesi,D.P., Broder,S., Mitsuya,H. and Barry,D.W. (1986) Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl Acad. Sci. USA, 83, 8333-8337.
10. HIV Trialists' Collaborative Group (1999) Zidovudine, didanosine and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. Lancet, 353, 2014-2025.
11. Huang,P., Farquhar,D. and Plunkett,W. (1990) Selective action of 3′-azido-3′-deoxythymidine 5′-triphosphate on viral reverse transcriptases and human DNA polymerases. J. Biol. Chem., 265, 11914-11918.
12. IARC (2000) Zidovudine (AZT). In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 76, Some Antiviral and Antineoplastic Drugs and Other Pharmaceutical Agents. IARC, Lyon, pp. 73-127.
13. Kewn,S., Hoggard,P.G., Henry-Mowatt,J.S., Veal,G.J., Sales,S.D., Barry,M.G. and Back,D.J. (1999) Intracellular activation of 2′,3′-dideoxyinosine and drug interactions in vitro. AIDS Res. Hum. Retroviruses, 15, 793-802.
14. Lewis,W. and Dalakas,M.C. (1995) Mitochondrial toxicity of antiviral drugs. Nature Med., 1, 417-422.
15. Meng,Q., Skopek,T.R., Walker,D.M., Hurley-Leslie,S., Chen,T., Zimmer,D.M. and Walker,V.E. (1998) Culture and propagation of Hprt mutant T-lymphocytes isolated from mouse spleen. Environ. Mol. Mutagen., 32, 236-243.
16. Meng,Q., Walker,D.M., Olivero,O.A., Shi,X., Antiochos,B.B., Poirier,M.C. and Walker,V.E. (2000) Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc. Natl Acad. Sci. USA, 97, 12667-12671.
17. Meng,Q., Su,T., O'Neill,J.P. and Walker,V.E. (2002) Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3′-azido-3′ -deoxythymidine and 2′,3′-dideoxyinosine. Environ. Mol. Mutagen., 39, 282-295.
18. +/- mice treated as neonates with 3′-azido-3′-deoxythymidine (AZT). Mutat. Res., 547, 63-69.
19. Navé,J.-F., Eschbach,A., Wolff-Kugel,D., Halazy,S. and Balzarini,J. (1994) Enzymatic phosphorylation and pyrophosphorylation of 2′,3′-dideoxyadenosine-5′-monophosphate, a key metabolite in the pathway for activation of the anti-HIV (human immunodeficiency virus) agent 2′,3′-dideoxyinosine. Biochem. Pharmacol., 48, 1105-1112.
20. Nickel,W., Austermann,S., Bialek,G. and Grosse,F. (1992) Interactions of azidothymidine triphosphate with the cellular DNA polymerases α, δ and E with DNA primase. J. Biol. Chem., 267, 848-854.
21. Olivero,O.A., Anderson,L.M., Diwan,B.A., Haines,D.C., Harbaugh,S.W., Moskal,T.J., Jones,A.B., Rice,J.M., Riggs,C.W., Logsdon,D., Yuspa,S.H. and Poirier,M.C. (1997) Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J. Natl Cancer. Inst., 89, 1602-1608.
22. Olivero,O.A., Shearer,G.M., Chougnet,C.A., Kovacs,A.A.S., Landay,A.L., Baker,R., Stek,A.M., Khoury,M.M., Proia,L.A., Kessler,H.A., Sha,B.E., Tarone,R.E. and Poirier,M.C. (1999) Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women and cord blood from infants exposed in utero. AIDS, 13, 919-925.
23. Palmer,S. and Cox,S. (1994) Intracellular metabolism of 3′-azido-3′-deoxythymidine and 2′,3′ -dideoxyinosine in combination in the absence and presence of ribavirin. Antiviral Chem. Chemother., 5, 403-409.
24. Palmer,S. and Cox,S. (1995) Intracellular activation and cytotoxicity of three different combinations of 3′-azido-3′-deoxythymidine and 2′,3′ -dideoxyinosine. AIDS Res. Hum. Retroviruses, 11, 1227-1233.
25. Peter,K. and Gambertoglio,J.G. (1998) Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection. Pharm. Res., 15, 819-825.
26. Poirier,M.C., Patterson,T.A., Slikker,W.,Jr and Olivero,O.A. (1999) Incorporation of 3′-azido-3′-deoxythymidine (AZT) into fetal DNA and fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose. J. Acquir. Immune Defic. Syndr., 22, 477-483.
27. Russell,J.W. and Klunk,L.J. (1989) Comparative pharmacokinetics of new anti-HIV agents: 2′,3′ -dideoxyadenosine and 2′,3′-dideoxyinosine. Biochem. Pharmacol., 38, 1385-1388.
28. Tinwell,H. and Ashby,J. (1989) Comparison of Acridine Orange and Giemsa stains in several mouse bone marrow micronucleus assays-including a triple dose study. Mutagenesis, 4, 476-481.
29. Trang,J.M., Prejean,J.D., James,R.H., Irwin,R.D., Goehl,T.J. and Page,J.G. (1993) Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice. Drug Metab. Dispos., 21, 189-193.
30. Vazquez-Padua,M.A., Starnes,M.C. and Cheng,Y.-c. (1990) Incorporation of 3′-azido-3′-deoxythymidine into cellular DNA and its removal in a human leukemic cell line. Cancer Commun., 2, 55-62.
31. Veal,G.J., Wild,M.J., Baffy,M.G. and Back,D.J. (1994) Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells. Br. J. Clin. Pharmacol., 38, 323-328.
32. +/- mice treated neonatally with zidovudine and lamivudine. Carcinogenesis, 23, 1427-1432.
33. Walker,V.E., Jones,I.M., Crippen,T.L., Meng,Q., Walker,D.M., Bauer,M.J., Reilly,A.A., Tates,A.D., Nakamura,J., Upton,P.B. and Skopek,T.R. (1999) Relationships between exposure, cell loss and proliferation, and manifestation of Hprt mutant T cells following treatment of preweanling, weanling, and adult male mice with N-ethyl-N-nitrosourea. Mutat. Res., 431, 371-388.
34. Wientjes,M.G. and Au,J.L.-S. (1992) Lack of pharmacokinetic interaction between intravenous 2′,3′-dideoxyinosine and 3′-azido-3′-deoxythymidine in rats. Antimicrob. Agents Chemother., 36, 665-668.
35. Williams,L.D., Von Tungeln,L.S., Beland,F.A. and Doerge,D.R. (2003) Liquid chromatographic-mass spectrometric determination of the metabolism and disposition of the anti-retroviral nucleoside analogs zidovudine and lamivudine in C57BL/6N and B6C3F1 mice. J. Chromatogr., 798, 55-62.
36. Wright,S.P. (1992) Adjusted P-values for simultaneous inference. Biometrics, 48, 1005-1013.